Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websites
July 28 2023 - 8:00AM
Biodexa Pharmaceuticals Launches New
Corporate and Clinical Trials Websites
Biodexa Pharmaceuticals PLC (NASDAQ: BDRX)
(“Biodexa” or the “Company”), a clinical stage
biopharmaceutical company developing a pipeline of products aimed
at primary and metastatic cancers of the brain is pleased to
announce that it has launched its new corporate website at
www.biodexapharma.com as well as a patient focused website aimed at
providing patients information about the therapeutic areas Biodexa
is studying in it’s ongoing clinical programmes:
www.resolvetrials.org.
New Corporate WebsiteOur new
website reflects the company’s evolution from a drug delivery
technology organisation to a drug development company focused on
rare / orphan diseases and oncology with a mission to advance the
development of medicines that offer patients a better future.
Clinical Trials SiteA critical
component of the drug development process is the evaluation of the
safety and efficacy of our investigational medicines in clinical
trials. We rely on, and appreciate the role of, volunteers who
enroll in our clinical programmes, because they help us better
understand the potential benefits and risks of our investigational
therapies.
Our newly launched reSOLVEtrials website aims to
inform patients who might be considering enrolling in a clinical
trial allowing them to better assess what may be involved and their
suitability for such study as well as providing details on the
location of studies and their principal investigators. This will
enable patients to contact the sites directly or discuss this
information with their treating physicians .
For more information, please contact:
Biodexa Pharmaceuticals PLC |
Stephen Stamp, CEO and CFO |
Tel: +44 29 20480 180 |
www.biodexapharma.com |
|
About Biodexa Pharmaceuticals PLC Biodexa
Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage
biopharmaceutical company developing a pipeline of products aimed
at primary and metastatic cancers of the brain. The Company’s lead
candidate, MTX110, is being studied in aggressive rare/orphan brain
cancer indications including recurrent glioblastoma and diffuse
midline glioma. MTX110 is a liquid formulation of the
histone deacetylase (HDAC) inhibitor, panobinostat. This
proprietary formulation enables delivery of the product via
convection-enhanced delivery (CED) at potentially chemotherapeutic
doses directly to the site of the tumour, by-passing the
blood-brain barrier and avoiding systemic toxicity. Biodexa is
supported by three proprietary drug delivery technologies focused
on improving the bio-delivery and bio-distribution of
medicines. Biodexa’s headquarters and R&D facility is in
Cardiff, UK. For more information visit
www.biodexapharma.com |
Forward-Looking
Statements
Certain statements in this announcement may
constitute "forward-looking statements" within the meaning of
legislation in the United Kingdom and/or United States. Such
statements are made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995 and are based on
management's belief or interpretation. All statements contained in
this announcement that do not relate to matters of historical fact
should be considered forward-looking statements.
Reference should be made to those documents that
Biodexa shall file from time to time or announcements that may be
made by Biodexa in accordance with the rules and regulations
promulgated by the US Securities and Exchange Commission, which
contains and identifies other important factors that could cause
actual results to differ materially from those contained in any
projections or forward-looking statements. These forward-looking
statements speak only as of the date of this announcement. All
subsequent written and oral forward-looking statements by or
concerning Biodexa or VarianBio are expressly qualified in their
entirety by the cautionary statements above. Except as may be
required under relevant laws in the United States, Biodexa does not
undertake any obligation to publicly update or revise any
forward-looking statements because of new information, future
events or otherwise arising.
Biodexa Pharmaceuticals (NASDAQ:BDRX)
Historical Stock Chart
From May 2024 to Jun 2024
Biodexa Pharmaceuticals (NASDAQ:BDRX)
Historical Stock Chart
From Jun 2023 to Jun 2024